Anónimo. Inotuzumab ozogamicine et leucémie aiguë lymphoblastique chez les adultes. Prescrire 2018;38:494-9. [Ref.ID 102757]

Anónimo. Blinatumomab et leucémie aiguë lymphoblastique chez les adultes. Prescrire 2018;38:97-9. [Ref.ID 102582]

Vaidya JS, Massarut S, Vaidya HJ, Alexander EC, Richards T, Caris JA, Sirohi B, Tobias JS. Rethinking neoadjuvant chemotherapy for breast cancer. BMJ 2018;360:j5913. [Ref.ID 102449]

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi C. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol 2017;83:2605-14. [Ref.ID 102170]

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-62. [Ref.ID 102081]

Anónimo. Ibrutinib et leucémie lymphoïde chronique en première ligne. Prescrire 2017;37:335-6. [Ref.ID 101645]

Anónimo. Érythrodysesthésies palmoplantaires des antitumoraux anti-VEGF. Prescrire 2017;37:30-1. [Ref.ID 101368]

Anónimo. Encéphalopathies postérieures réversibles d'origine médicamenteuse. Prescrire 2016;36:907-10. [Ref.ID 101007]

Anónimo. Carfilzomib et myélome multiple. Prescrire 2016;36:885-6. [Ref.ID 101002]

Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R. Tratamiento de las gestantes con enfermedades reumáticas o autoinmunitarias sistémicas con fármacos inmunodepresores y biológicos. Med Clin (Barc) 2016;147:352-60. [Ref.ID 100793]

Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]

Mayor S. “Impressive results” in stem cell treatment for multiple sclerosis. BMJ 2016;353:i3269. [Ref.ID 100429]

Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker L-M, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:2402-11. [Ref.ID 100407]

Anónimo. Ofatumumab et leucémie lymphoïde chronique en première ligne. Prescrire 2015;35:416-7. [Ref.ID 99422]

Anónimo. Obinutuzumab. Prescrire 2015;35:414-5. [Ref.ID 99421]

Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F, for the Gruppo Italiano Mammella (GIM) investigators. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2?×?2 factorial, randomised phase 3 trial. Lancet 2015;385:1863-72. [Ref.ID 99090]

Robak T, Huang H, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F, for the LYM-3002 Investigators. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 2015;372:944-53. [Ref.ID 98932]

Anónimo. Bortézomib en association dans le myélome multiple. Prescrire 2015;35:182-3. [Ref.ID 98926]

Llop R. Fármacos y alopecia. Formación Médica Continuada en Atención Primaria 2014;21:293-7. [Ref.ID 97542]